The graph showed a flat line with a single sharp spike in the middle
Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, Quinnan LA, Shirazian S, Liang C, Podar K, Christensen JG, Salgia R
NOX3 inhibitors;Cannabinoid2 receptor activators/modulators
"I don't believe for one moment that what's going on here is an honest investigation of whether these products should be compounded." Scott Brunner of the Alliance for Pharmacy Compounding said the coming meeting will be the start of a "protracted process." Even if the panel votes to make the peptides available, and FDA agrees, the agency will still have to draft and publish rules on the change, he noted